eBook + CHOICES Intervention for Sickle Cell Disease
(CHOICES3 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a web-based program called CHOICES, designed to assist individuals with sickle cell disease (SCD) or sickle cell trait (SCT) in planning for children without SCD. Participants will either use this program or read an eBook about SCD and SCT. The goal is to determine if these tools can aid individuals in making informed reproductive choices. Individuals with SCD or SCT who plan to have a child in the next two years and wish to avoid passing on SCD might be well-suited for this trial. As an unphased trial, this study provides a unique opportunity to contribute to innovative research that could empower future family planning decisions.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that the CHOICES program is safe for individuals with sickle cell disease (SCD) or sickle cell trait (SCT). Past studies have demonstrated that CHOICES helps young adults understand genetic inheritance and plan for healthy pregnancies. No reports of harmful effects have emerged from using this program.
CHOICES serves as an educational tool rather than a typical medical treatment. It provides information to help individuals make informed decisions about their reproductive health. As a web-based program, it does not involve medication or medical procedures, making it generally safe and easy to use.
Prospective participants in a trial with the CHOICES program can feel assured that it is designed to help without causing harm.12345Why are researchers excited about this trial?
Researchers are excited about the CHOICES intervention for sickle cell disease because it offers a novel approach to reproductive education through a web-based platform specifically designed for individuals with sickle cell disease or trait. Unlike traditional educational methods, which may involve in-person consultations or generalized resources, this digital format provides tailored and easily accessible information that can empower patients in managing their reproductive health. The use of technology to deliver personalized education could potentially increase engagement and understanding, making it a promising tool for improving patient outcomes.
What evidence suggests that this trial's treatments could be effective for sickle cell disease?
Research has shown that the CHOICES program, which participants in this trial may receive, can assist individuals with sickle cell disease (SCD) or sickle cell trait (SCT) who are planning to have children. In earlier studies, participants in the CHOICES group were more likely to create a plan to prevent having a child with SCD or SCT. They were more than twice as likely to take this proactive step compared to those who did not join the program. This suggests that CHOICES helps individuals understand genetic risks and make informed family planning decisions.12567
Who Is on the Research Team?
Diana Wilkie, PhD
Principal Investigator
University of Florida
Are You a Good Fit for This Trial?
This trial is for adults aged 18-45 with Sickle Cell Disease (SCD) or Sickle Cell Trait (SCT), who can read and speak English, want to conceive within the next two years, and aim to have a child free of SCD. It's not open to those who've been in CHOICES studies before, are unable to complete study tasks, or cannot have children due to medical reasons.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive web-based reproductive education and tailored interventions for sickle cell disease or trait
Follow-up
Participants are monitored for knowledge retention and behavior changes after intervention
What Are the Treatments Tested in This Trial?
Interventions
- CHOICES
- eBook
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Florida
Lead Sponsor
National Human Genome Research Institute (NHGRI)
Collaborator